AI assistant
TENAX THERAPEUTICS, INC. — Director's Dealing 2025
May 21, 2025
34835_dirs_2025-05-20_f84d9213-1f21-4530-ab69-a403f47fb90a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TENAX THERAPEUTICS, INC. (TENX)
CIK: 0000034956
Period of Report: 2025-05-16
Reporting Person: Giordano Christopher Thomas (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-16 | Stock Option (right to buy) | $5.89 | A | 1400000 | Acquired | 2035-05-16 | Common Stock (1400000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $3152 | 2031-07-06 | Common Stock (157) | 157 | Direct |
| Stock Option (right to buy) | $992 | 2032-06-09 | Common Stock (125) | 125 | Direct |
| Stock Option (right to buy) | $3.549 | 2034-05-17 | Common Stock (437) | 437 | Direct |
| Stock Option (right to buy) | $5.94 | 2034-12-10 | Common Stock (1250000) | 1250000 | Direct |
Footnotes
F1: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
F2: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.
F3: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
F4: The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.